TerminatedPHASE1, PHASE2NCT05405257

Oxytocin for Hypermobile Ehlers-Danlos Syndrome

Studying Ehlers-Danlos syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Baylor College of Medicine
Principal Investigator: Brendan Lee, MD, PhD
Baylor College of Medicine
Intervention: Oxytocin(drug)
Enrollment: 2 enrolled
Eligibility: 18-64 years · FEMALE
Timeline: 2022 – 2025

Study locations (1)

Baylor College of Medicine, Houston, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05405257 on ClinicalTrials.gov

Other trials for Ehlers-Danlos syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT05561270
Light Exposure on Pain in Hypermobile Ehlers-Danlos Syndrome
New York Institute of Technology
ACTIVE NOT RECRUITINGPHASE4NCT05603741
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers
University of Calgary
ACTIVE NOT RECRUITINGNANCT04036305
Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers
Vanderbilt University Medical Center
ACTIVE NOT RECRUITINGEARLY PHASE1NCT03686748
Two Point Discrimination
Children's Hospital Medical Center, Cincinnati
ACTIVE NOT RECRUITINGNCT05976841
SEDVasc (RaDiCo Cohort) (RaDiCo-SEDVasc)
Institut National de la Santé Et de la Recherche Médicale, France
RECRUITINGNCT04133272
Registry of Ehlers-Danlos Syndrome
Luca Sangiorgi

See all trials for Ehlers-Danlos syndrome →

← Back to all trials